156 filings
Page 5 of 8
6-K
4ryz8ys0xnhtwusdw0
18 Jul 16
Current report (foreign)
12:00am
6-K
kok1pp9 ceg12ulxbx1
14 Jul 16
Current report (foreign)
12:00am
6-K
b3scjw
12 Jul 16
Current report (foreign)
12:00am
6-K
apmvlsoc
27 Jun 16
GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome
12:00am
6-K
yrav50x
21 Jun 16
Current report (foreign)
12:00am
6-K
spjxb2cas9x7c
13 May 16
Current report (foreign)
12:00am
6-K
5nxag
5 May 16
GW Pharmaceuticals plc Reports Second Quarter and Half-Year 2016 Financial Results and Operational Progress
12:00am
6-K
ifnu0dbv
25 Apr 16
GW Pharmaceuticals Receives Orphan Drug Designation from FDA for Cannabidiol for the Treatment of Tuberous Sclerosis Complex
12:00am
6-K
jr9dpmh6vpa2hg
11 Apr 16
Current report (foreign)
12:00am
6-K
qy62p41gyq ceeg2
1 Apr 16
Current report (foreign)
12:00am
6-K
g4glbi1vb9 87
14 Mar 16
Current report (foreign)
12:00am
6-K
vdz39de
19 Feb 16
Current report (foreign)
12:00am
6-K
3yhuc8ugrxf fl
10 Feb 16
GW Pharmaceuticals plc Reports First Quarter 2016 Financial Results and Operational Progress
12:00am
6-K
2irce5usqysl23wgp
29 Dec 15
Current report (foreign)
12:00am
6-K
3qccmyavy
28 Dec 15
Current report (foreign)
12:00am
6-K
lx6wab
22 Dec 15
Current report (foreign)
12:00am
6-K
wra73ec87hbatd0qw4
7 Dec 15
GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2015 Financial Results and Operational Progress
12:00am
6-K
lrf4rf2l9n1i u7v
25 Nov 15
New Epidiolex® (CBD) Data Accepted for Presentation at the 69th Annual Meeting of the American Epilepsy Society
12:00am
6-K
sld801
28 Oct 15
Current report (foreign)
12:00am
6-K
wduvi2kzyys cmf7zcq
16 Sep 15
GW Pharmaceuticals Announces Positive Proof of Concept Data in Schizophrenia
12:00am